162 related articles for article (PubMed ID: 28898590)
1. Biosimilars: Reimbursement Issues in Your Oncology Practice.
Conti RM
J Oncol Pract; 2017 Sep; 13(9_suppl):12s-14s. PubMed ID: 28898590
[No Abstract] [Full Text] [Related]
2. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
Lyman GH
J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
[No Abstract] [Full Text] [Related]
3. Biosimilars in oncology: everybody agrees but nobody uses?
Gyawali B
Recenti Prog Med; 2017 Apr; 108(4):172-174. PubMed ID: 28492585
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in Oncology: Reality Could Bite the Copycats, Dog Potential Major Savings.
Kelley T
Manag Care; 2017 Mar; 26(3):28-30. PubMed ID: 28510517
[TBL] [Abstract][Full Text] [Related]
5. Introduction and commentary: Paving the way for biosimilars in oncology.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
[No Abstract] [Full Text] [Related]
6. Likelihood of use and perception towards biosimilars in rheumatoid arthritis: a global survey of rheumatologists.
Narayanan S; Nag S
Clin Exp Rheumatol; 2016; 34(1 Suppl 95):S9-11. PubMed ID: 26146845
[No Abstract] [Full Text] [Related]
7. [The development of biosimilars in oncology].
Jiang SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):721-725. PubMed ID: 29061013
[TBL] [Abstract][Full Text] [Related]
8. How do biosimilars sustain value, affordability, and access to oncology care?
Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):327-329. PubMed ID: 32842809
[No Abstract] [Full Text] [Related]
9. Tracking the price of existing biologics when drugs enter the market.
Stiff KM; Cline A; Feldman SR
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):375-377. PubMed ID: 31177860
[No Abstract] [Full Text] [Related]
10. Biosimilars.
Bagel J
J Drugs Dermatol; 2014 Jul; 13(7):788-90. PubMed ID: 25007360
[No Abstract] [Full Text] [Related]
11. A long war begins: biosimilars versus patented biologics.
Bocquet F; Paubel P
J Med Econ; 2015; 18(12):1071-3. PubMed ID: 26212478
[No Abstract] [Full Text] [Related]
12. From the editor-in-chief: new ways to pay for cures.
Alvarnas J
Am J Manag Care; 2019 Jun; 25(6 Spec No.):SP185. PubMed ID: 31233305
[No Abstract] [Full Text] [Related]
13. Forum discusses biosimilars, better biologicals.
Thompson CA
Am J Health Syst Pharm; 2011 Dec; 68(23):2210. PubMed ID: 22095804
[No Abstract] [Full Text] [Related]
14. Postmarket policy considerations for biosimilar oncology drugs.
Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
[TBL] [Abstract][Full Text] [Related]
15. A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.
Wehrwein P
Manag Care; 2019 Jan; 28(1):12-15. PubMed ID: 30883317
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars.
Ross A; Richard K
Conn Med; 2015 May; 79(5):295-9. PubMed ID: 26245019
[No Abstract] [Full Text] [Related]
17. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
Neumann D; Jabłecka A
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
[TBL] [Abstract][Full Text] [Related]
18. What are biosimilars and are they important?
Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
[TBL] [Abstract][Full Text] [Related]
19. Empower physicians to fight financial toxicity with biosimilars.
Oubre K
Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP374-SP375. PubMed ID: 31860250
[No Abstract] [Full Text] [Related]
20. A clinician's guide to biosimilars in oncology.
Rugo HS; Linton KM; Cervi P; Rosenberg JA; Jacobs I
Cancer Treat Rev; 2016 May; 46():73-9. PubMed ID: 27135548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
